Christina Lake Cannabis Corp. (CSE: CLC) has announced it received an unsolicited offer from Medical Saints Ltd. to acquire substantially all of its assets for $18,000,000, representing a competing proposal to an earlier $15,000,000 share-acquisition offer disclosed on August 21, 2026. The company has entered into a non-binding letter of intent with Medical Saints, effective September 11, 2026, while its Special Committee continues to evaluate both proposals. No definitive agreement has been approved by the Board for either transaction, making the outcome uncertain for investors watching the stock.

Key Points

  • Christina Lake Cannabis Corp. (CSE: CLC, OTCQB: CLCFF, Frankfurt: CLB) announced a second acquisition proposal on September 15, 2026
  • Medical Saints Ltd. has proposed acquiring substantially all CLC assets for $18,000,000 cash, compared to the original $15,000,000 share-acquisition offer
  • A $2,000,000 advance payment is contemplated under the Second LOI, credited against the purchase price at closing; parties have a 40-day exclusivity window to negotiate a definitive agreement
  • Investors should watch for Special Committee recommendations and any shareholder meeting announcement tied to a definitive agreement

Structure of the Medical Saints Alternative Transaction

Unlike the original proposal, which contemplated acquiring all issued CLC shares, the Medical Saints offer targets substantially all company assets — including owned land, buildings, machinery, inventory, trademarks, patents, and customer lists — on a cash-free, debt-free basis, excluding cash equivalents, tax receivables, and certain other agreed assets. The $18,000,000 purchase price is payable in cash at closing. Medical Saints is described in the release as one of Canada's largest privately held federally licensed cannabis producers, currently producing 100 tonnes of cannabis annually across a vertically integrated platform.

Advance Payment Mechanics and Exclusivity Terms

The Second LOI contemplates a $2,000,000 advance payment delivered concurrently with the signing of a definitive agreement, held by the company's counsel for the benefit of CLC and credited against the purchase price at closing. The release states that in certain circumstances where the transaction fails due to the Alternative Purchaser's default or material breach, CLC would retain the advance as liquidated damages. The parties have a 40-day exclusivity period from execution of the Second LOI to negotiate and enter into a definitive agreement, expressly subject to the Board's fiduciary duties and existing obligations under the original letter of intent.

Special Committee Evaluating Both CLC Transaction Proposals Simultaneously

The Special Committee of the Board, formed in August 2026, is concurrently reviewing both the original proposal from the unnamed Alberta corporation and the Medical Saints alternative. The release confirms the Board has not approved a definitive agreement for either transaction. Should a definitive agreement be executed with Medical Saints, CLC expects to hold a special shareholder meeting for approval, with terms disclosed in a management information circular. The release notes no finder's fees are payable in connection with the Alternative Transaction, and Prelia Canada LLP is acting as legal advisor to the company.